CC-4047-MM-015- Pomalidomide For Relapsed And Refractory MM ...

HRA Health Research Authority Protecting and promoting the interests of patients and the public in health research. The Health Research Authority website uses essential cookies

This site uses session cookies and persistent cookies to improve the content and structure of the site.

By clicking “Accept All Cookies”, you agree to the storing of cookies on this device to enhance site navigation and content, analyse site usage, and assist in our marketing efforts.

By clicking 'See cookie policy' you can review and change your cookie preferences and enable the ones you agree to.

By dismissing this banner, you are rejecting all cookies and therefore we will not store any cookies on this device.

Accept all cookies See cookie policy Glossary Search glossary CC-4047-MM-015- Pomalidomide for relapsed and refractory MM patients

• Research type

  Research Study

• Full title

  A non-interventional post authorisation registry of patients treated with pomalidomide for relapsed and refractory multiple myeloma who have received at least two prior treatment regimens, including both lenalidomide and bortezomib, and have demonstrated disease progression on the last therapy.

• IRAS ID

  156084

• Contact name

  Graham Jackson

• Contact email

  graham.jackson@newcastle.ac.uk

• Sponsor organisation

  Celgene Europe Limited

• Clinicaltrials.gov Identifier

  EU/1/13/850/001-004, Product reference

• Research summary

  Multiple myeloma is an incurable cancer of plasma cells (a type of immune cell that produces antibodies) in the bone marrow. Imnovid has been approved for the treatment of multiple myeloma in the United Kingdom.The purpose of this study is to collect additional safety data for the safety profile of pomalidomide in a non-interventional post-authorisationsetting in previously treated multiple myeloma patients, to enhance real world safety knowledge, beyond the clinical trial safety data previously collected. It is not the purpose of this study to test a new experimental product.

• REC name

  North West - Greater Manchester East Research Ethics Committee

• REC reference

  14/NW/1314

• Date of REC Opinion

  17 Sep 2014

• REC opinion

  Unfavourable Opinion

Stay up to date with latest news, updates to regulations and upcoming learning events © Copyright HRA 2024

• Contact us
• Privacy notice
• Terms & conditions
• Accessibility statement
• Feedback or concerns

Site by Big Blue Door